The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
 
Changqing Xie
No Relationships to Disclose
 
M. Cecilia Monge B.
No Relationships to Disclose
 
Donna Mabry-Hrones
No Relationships to Disclose
 
Kelley Lauren Coffman
No Relationships to Disclose
 
Stephanie Hicks
No Relationships to Disclose
 
Bernadette Redd
No Relationships to Disclose
 
Brad Wood
No Relationships to Disclose
 
Steven Highfill
No Relationships to Disclose
 
Mitchell Ho
Research Funding - crispr therapeutics (Inst); Cytovia Therapeutics (Inst); NeoImmuneTech (Inst); Xyphos (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to antibodies, CAR-T, and other therapeutics targeting GPC3, GPC2, GPC1, mesothelin, B7-H3, PD-L1, SARS-CoV-2, and Lassa. (Inst)
 
Tim F. Greten
No Relationships to Disclose